收稿日期: 2024-08-26
网络出版日期: 2024-12-18
版权
李春 , 胡晓丹 . 关注血栓性抗磷脂综合征的长期抗凝[J]. 北京大学学报（医学版）, 2024 , 56(6) : 947 -949 . DOI: 10.19723/j.issn.1671-167X.2024.06.001
| 1 | Barilaro G , Esteves A , Della-Rocca C , et al. Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: A longitudinal study[J]. Rheumatology (Oxford), 2023, 62 (4): 1576- 1585. |
| 2 | Cervera R , Serrano R , Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients[J]. Ann Rheum Dis, 2015, 74 (6): 1011- 1018. |
| 3 | Sevim E , Zisa D , Andrade D , et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository[J]. Arthritis Care Res (Hoboken), 2022, 74 (2): 324- 335. |
| 4 | Cervera R , Rodríguez-Pintó I , Espinosa G . The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review[J]. J Autoimmun, 2018, 92, 1- 11. |
| 5 | Tektonidou MG , Andreoli L , Limper M , et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019, 78 (10): 1296- 1304. |
| 6 | Crowther MA , Ginsberg JS , Julian J , et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome[J]. N Engl J Med, 2003, 349 (12): 1133- 1138. |
| 7 | Finazzi G , Marchioli R , Brancaccio V , et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)[J]. J Thromb Haemost, 2005, 3 (5): 848- 853. |
| 8 | Pengo V , Denas G , Zoppellaro G , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome[J]. Blood, 2018, 132 (13): 1365- 1371. |
| 9 | Ordi-Ros J , Sáez-Comet L , Pérez-Conesa M , et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial[J]. Ann Intern Med, 2019, 171 (10): 685- 694. |
| 10 | Pengo V , Testa S , Martinelli I , et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant[J]. Thromb Res, 2015, 135 (1): 46- 49. |
| 11 | Yelnik CM , Urbanski G , Drumez E , et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity[J]. Lupus, 2017, 26 (2): 163- 169. |
| 12 | Mustonen P , Lehtonen KV , Javela K , et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study[J]. Lupus, 2014, 23 (14): 1468- 1476. |
| 13 | Ruffatti A , Del-Ross T , Ciprian M , et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A prospective multicentre follow-up study[J]. Ann Rheum Dis, 2011, 70 (6): 1083- 1086. |
| 14 | Zuo Y , Barbhaiya M , Erkan D . Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: Where do we stand in 2018[J]. Curr Rheumatol Rep, 2018, 20 (11): 66. |
| 15 | Erkan D , Harrison MJ , Levy R , et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals[J]. Arthritis Rheum, 2007, 56 (7): 2382- 2391. |
| 16 | Arnaud L , Mathian A , Ruffatti A , et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis[J]. Autoimmun Rev, 2014, 13 (3): 281- 291. |
| 17 | Arnaud L , Mathian A , Devilliers H , et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies[J]. Autoimmun Rev, 2015, 14 (3): 192- 200. |
| 18 | Watanabe T , Oku K , Amengual O , et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies[J]. Lupus, 2018, 27 (2): 225- 234. |
| 19 | Erkan D , Willis R , Murthy VL , et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients[J]. Ann Rheum Dis, 2014, 73 (6): 1176- 1180. |
| 20 | Cohen H , Cuadrado MJ , Erkan D , et al. 16th International Congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends[J]. Lupus, 2020, 29 (12): 1571- 1593. |
| 21 | Erkan D , Unlu O , Sciascia S , et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease[J]. Lupus, 2018, 27 (3): 399- 406. |
| 22 | Cohen H , Sayar Z , Efthymiou M , et al. Management of anticoagulant-refractory thrombotic antiphospholipid syndrome[J]. Lancet Haematol, 2020, 7 (8): e613- e623. |
| 23 | Mormile I , Granata F , Punziano A , et al. Immunosuppressive treatment in antiphospholipid syndrome: Is it worth it?[J]. Biomedicines, 2021, 9 (2): 132. |
| 24 | Rodríguez-Pintó I , Espinosa G , Erkan D , et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients[J]. Rheumatology (Oxford), 2018, 57 (7): 1264- 1270. |
| 25 | Berman H , Rodríguez-Pintó I , Cervera R , et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab[J]. Autoimmun Rev, 2013, 12 (11): 1085- 1090. |
| 26 | Yelnik CM , Miranda S , Mékinian A , et al. Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab[J]. Blood, 2020, 136 (21): 2473- 2477. |
| 27 | Bala MM , Celinska-Lowenhoff M , Szot W , et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome[J]. Cochrane Database Syst Rev, 2020, 10 (10): CD012169. |
| 28 | Yelnik CM , Erton ZB , Drumez E , et al. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ("Registry")[J]. Semin Arthritis Rheum, 2024, 65, 152347. |
| 29 | Medina G , Briones-García E , Cruz-Domínguez MP , et al. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence[J]. Autoimmun Rev, 2017, 16 (4): 352- 354. |
| 30 | Radin M , Schreiber K , Sciascia S , et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: A long-term follow-up multicentre study[J]. Thromb Haemost, 2019, 119 (12): 1920- 1926. |
| 31 | Zen M , Loredo-Martinez M , Benvenuti F , et al. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion[J]. Rheumatology (Oxford), 2021, 60 (3): 1313- 1320. |
| 32 | Cuadrado MJ , Tincani A , Enriquez-Merayo E , et al. Can anticoagulation be withdrawn in APS patients after aPL negativization[J]. Autoimmun Rev, 2024, 23 (1): 103427. |
| 33 | Ballul T , Mageau A , Roland Nicaise P , et al. Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome[J]. Thromb Res, 2023, 224, 1- 3. |
| 34 | Perez-Sanchez C , Barbarroja N , Messineo S , et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus[J]. Ann Rheum Dis, 2015, 74 (7): 1441- 1449. |
/
| 〈 |
|
〉 |
